Please provide your email address to receive an email when new articles are posted on . Datopotamab deruxtecan failed to extend OS vs. chemotherapy for adults with advanced breast cancer, according to ...

SAN DIEGO -- The addition of an immune checkpoint inhibitor (ICI) to chemotherapy up front improved overall survival (OS) in patients with advanced or recurrent endometrial cancer, regardless of ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A new combination therapy benefitted certain patients with immunotherapy-resistant advanced non-small ...